Tara Anderson
Staff Affiliate - YNHHAbout
Titles
Staff Affiliate - YNHH
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Tara Anderson's published research.
Publications Timeline
A big-picture view of Tara Anderson's research output by year.
Francine Foss, MD
Iris Isufi, MD
Lohith Gowda, MD, MRCP
Manoj M Pillai, MBBS
Natalia Neparidze, MD
Noffar Bar, MD
1Publications
Publications
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
Clinical Trials
Current Trials
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
HIC ID2000033033RoleSub InvestigatorPrimary Completion Date06/18/2027Recruiting ParticipantsA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis
HIC ID2000030933RoleSub InvestigatorPrimary Completion Date06/30/2024Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
HIC ID2000029969RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
HIC ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Medical Oncology; Hematology & Oncology
Board Certifications
Physician Assistant - Medical
- Certification Organization
- National Commission on Certification of Physician Assistants
- Original Certification Date
- 2001
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor Profile